Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
Amgen's Q2 sales suffer from weak demand and reform costs
30 July 2010
A $45 million hit from US healthcare reform costs and weak demand for the anaemia drug Aranesp (darbepoetin alfa) forced Amgen's second-quarter sales down by ...
US FDA advisors add uncertainty to Pfizer's bid for longer sildenafil exclusivity
30 July 2010
After the 29 July meeting of the US FDA's cardio-renal advisory committee meeting, which discussed a paediatric indication for Pfizer's pulmonary arterial ...
US FDA advisors back AstraZeneca's Brilinta for thrombotic events
29 July 2010
AstraZeneca gained substantial support on 28 July from the US FDA's advisory committee on cardiovascular and renal drugs for its potential blockbuster blood ...
Sanofi-Aventis fuels Genzyme buyout rumours after Q2 income jump
29 July 2010
Sanofi-Aventis is reportedly set to make an offer for Genzyme after posting a 61% rise in second-quarter net income to €1.8 billion. The French firm's CEO ...
 
UCB products give Actient a platform for growth in urology
30 July 2010
Actient Pharmaceuticals, a new speciality company formed last year in the US with funding from private equity firm GTCR, has established a platform for commercial growth by licensing and acquiring ...
Celgene raises guidance again as income jumps 50%
30 July 2010
Celgene has followed up last month's agreement to acquire Abraxis Bioscience for $2.9 billion with a strong set of results for the second quarter, prompting the company once again to raise its ...
Centaur readies US plan to boost exports
30 July 2010
Centaur Pharmaceuticals of India expects exports to emerge as a significant contributor to revenues in the next few years, as it readies to tap the US market. Centaur's managing director, S D ...
Olmesartan strong for Daiichi Sankyo as it builds up vaccines activities
30 July 2010
Daiichi Sankyo has reported a generally strong first quarter, in which global sales of its top product, the antihypertensive olmesartan, rose by 8% to ¥60.2 billion ($689.6 million; including in ...
 
A phoenix rises from the ashes of GSK's Avandia?
30 July 2010
Concerns over the cardiovascular safety of GlaxoSmithKline's diabetes therapy Avandia (rosiglitazone) have generated bad press for the PPARγ agonists of late, but a recent study in Nature suggests ...
Questions remain about Provenge, says NEJM editorial
29 July 2010
The publication of the pivotal IMPACT trial of Dendreon's Provenge (sipuleucel-T) in the NEJM has highlighted that many questions still surround the first therapeutic vaccine to be approved in the ...
US FDA approves Shionogi's Cuvposa for drooling
29 July 2010
The US FDA has approved Shionogi Pharma's Cuvposa (glycopyrrolate) for the treatment of severe drooling (ptyalism) caused by neurologic disorders in children aged 3-16 years. The muscarinic receptor ...
Merck Serono's oral MS drug cladribine given US priority review
28 July 2010
The NDA for Merck Serono's oral relapsing-remitting multiple sclerosis (RRMS) drug cladribine tablets has been accepted by the US FDA, who also designated it with a priority review status. This ...
 
Spanish medicine price discounts kick in
30 July 2010
Obligatory 7.5% discounts on medicines in Spain, which came in to force on 1 June are already paying off for the government. This week it announced that the amount it paid per prescription had fallen ...
US court invalidates Lilly's Gemzar method-of-use patent
30 July 2010
A US appeals court has upheld a previous ruling invalidating Lilly's method-of-use patent for its anticancer, Gemzar (gemcitabine HCl for injection). The ruling is expected to clear the path for the ...
UK to implement early access scheme for promising drugs
30 July 2010
A UK scheme for giving patients access to promising new medicines that have completed their clinical trial programmes but are not yet licensed for marketing is expected to be implemented later this ...
FDA sees GMP lapses at a third J&J plant
30 July 2010
Details have emerged on how US FDA inspectors observed a number of good manufacturing practice (GMP) deficiencies at a third Johnson & Johnson plant. This time they relate to Johnson & Johnson Merck ...
 
PEOPLE
Promotion at Dynavax Dr Tyler Martin has been promoted from chief medical officer to the newly created position of ...
Alexza Pharmaceuticals makes board appointment Alexza Pharmaceuticals (US) has elected Joseph Turner to its board of directors and as chair of the ...
New appointment at Nile Therapeutics Nile Therapeutics, a US-based biopharmaceutical company developing therapeutics for cardiovascular ...
>> More People News...

EXPERT VIEW
What the extra cash for cancer drugs in the UK really means
30 July 2010
Peter Charlish
At first sight, the recent announcement in the UK that £50 million is to be made available as an ...

ObamaCare: Here comes change
30 July 2010

President Barack Obama's commitment to health reform was unmistakeable in February 2009, when he ...

 ObamaCare: Something for everyone...
 ObamaCare: The stuff of dreams...

Rare diseases in the Middle East: prospects for CROs
28 July 2010

The treatment of rare diseases in Europe has been significantly enhanced by the EU's Orphan Drug ...

ObamaCare: The stuff of dreams
23 July 2010

Assessing the impact of the reform on pharma is a cost-benefit exercise. The industry will have to ...

MULTIMEDIA
Scrip Roundtable June 2010 - Emerging Markets: The New Generation 02 July 2010

Get the Flash Player to see this player.

Value-based pricing for drugs: is the NHS willing to pay?
20 July 2010
Elizabeth Sukkar
Those civil servants who mill around Whitehall are quietly working on what may encompass a whole ...

Calling German and Spanish Physicists: the EMA Needs You
13 July 2010
Maureen Kenny
German or Spanish physicists hoping for a career change involving a move to London at the end of ...

Face-to-Face: Trophos - The French firm that hooked Actelion
23 July 2010
Simon Varcoe
Actelion this week acquired the option to buy private company Trophos, with the final decision ...

Scrip Asia 100
30 June 2010
Scrip's analysis of the pharmaceutical industry's performance and prospects in Asia The ...

JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm